Wenxia Xu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Cisplatin is the first-line agent utilized for the clinical treatment of a wide variety of solid tumors including gastric cancer. However, the intrinsic or acquired cisplatin resistance is often occurred in patients with gastric cancer and resulted in failure of cisplatin therapy. In order to investigate if miRNA involves in cisplatin resistance of human(More)
  • 1